Mise en abyme meaning "placed into abyss or infinite recurrence" is an apt paradigm for the relentless growth of sarcoma cells. Its alternative meaning, "self-reflexive embedding" fits the central role attributed to cancer stem cells (CSCs). Diversely sourced and defined, mesenchymal stem cells (MSCs) may be the cells of sarcoma origin, evolve a CSC phenotype and/or contribute to tumor growth through inherent qualities for homing, neovascularization, paracrine cross-feeding, microvesicle secretion, cell fusion, entosis and immune modulation. Exploiting these qualities, MSC expressing modified forms of the TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) are being developed to complement more conventional radiation and chemotherapy.
Sarcomas as a mise en abyme of Mesenchymal Stem Cells; exploiting interrelationships for cell mediated anticancer therapy / J. S., Burns; A., Safwat; Grisendi, Giulia; M., Kassem; Dominici, Massimo. - In: CANCER LETTERS. - ISSN 0304-3835. - STAMPA. - 325:(2012), pp. 1-10. [10.1016/j.canlet.2012.05.027]
Sarcomas as a mise en abyme of Mesenchymal Stem Cells; exploiting interrelationships for cell mediated anticancer therapy
GRISENDI, Giulia;DOMINICI, Massimo
2012
Abstract
Mise en abyme meaning "placed into abyss or infinite recurrence" is an apt paradigm for the relentless growth of sarcoma cells. Its alternative meaning, "self-reflexive embedding" fits the central role attributed to cancer stem cells (CSCs). Diversely sourced and defined, mesenchymal stem cells (MSCs) may be the cells of sarcoma origin, evolve a CSC phenotype and/or contribute to tumor growth through inherent qualities for homing, neovascularization, paracrine cross-feeding, microvesicle secretion, cell fusion, entosis and immune modulation. Exploiting these qualities, MSC expressing modified forms of the TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) are being developed to complement more conventional radiation and chemotherapy.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Burns et al MSC and Sarcomas_Cancer Letter 2012.pdf
Accesso riservato
Tipologia:
Versione originale dell'autore proposta per la pubblicazione
Dimensione
730.68 kB
Formato
Adobe PDF
|
730.68 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
